Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK2190915 milled · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Period 1 Cohort 1 - GSK2190915 100mg | EXPERIMENTAL | Period 1 - GSK2190915 100mg tablet. |
| Period 1 Cohort 2 - GSK2190915 100mg plus microtracer | EXPERIMENTAL | Period 1 - GSK2190915 100mg tablet plus \[14C\] radiolabelled GSK2190915 microtracer solution. |
| Period 2 GSK2190915 100mg to proximal small bowel | EXPERIMENTAL | 100mg of ground half 200mg GSK2190915 tablet administered to the proximal small bowel via Enterion capsule. |
| Period 3 GSK2190915 100 mg to distal small bowel | EXPERIMENTAL | 100mg of ground half 200mg GSK2190915 tablet administered to the distal small bowel via Enterion capsule. |
| Period 4 - GSK 100mg enteric-coated tablet | EXPERIMENTAL | 100mg enteric-coated GSK2190915 coated tablet. |
| Name | Type | Description |
|---|---|---|
| GSK2190915 100mg milled tablet | DRUG | Taken orally |
| [14C] radiolabelled GSK2190915 solution | DRUG | Microtracer solution |
| GSK2190915 100mg milled tablet administered to the proximal small bowel. | DRUG | Ground half of a 200mg tablet. Administered via Enterion capsule. |
| GSK2190915 100mg milled tablet administered to the distal small bowel. | DRUG | Ground half of a 200mg tablet. Administered via Enterion capsule. |
| GSK2190915 100mg enteric-coated tablet. | DRUG | Taken orally |
Inclusion Criteria: * Healthy females as determined by an experienced study physician, based on a medical evaluation including medical history, physical examination, neurological examination, laboratory tests and electrocardiogram (ECG). A subject with a clinical abnormality or laboratory parameter...
GSK2190915 milled is an investigational small molecule being developed for the treatment of asthma. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and efficacy in humans.
GSK2190915 milled is being developed by GSK plc, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol GSK. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in healthy volunteers.
GSK2190915 milled is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being studied in early-stage trials to assess its absorption and bioavailability in the body.
GSK2190915 milled has one completed clinical trial registered under NCT01318980, titled 'A Single Dose Study to Assess the Regional Absorption and Bioavailability of 100mg GSK2190915A.' This Phase 1 study enrolled 14 female participants in the United Kingdom and was a controlled, non-randomized trial.
Yes, GSK2190915 milled is the same compound as GSK2190915A. The clinical trial NCT01318980 refers to the drug as GSK2190915A, and the milled formulation is the specific version being studied for its absorption and bioavailability characteristics.